Saphnelo (Anifrolumab) in Lupus
Administer anifrolumab 300 mg intravenously over 30 minutes every 4 weeks for adults with moderate to severe systemic lupus erythematosus who remain active despite standard therapy. 1
Indication and Patient Selection
Anifrolumab is FDA-approved for moderate to severe SLE in adults receiving standard therapy 1. The 2024 EULAR guidelines recognize anifrolumab as having proven efficacy through high-quality randomized controlled trials with low risk of bias for extrarenal SLE 2.
Critical limitation: Do NOT use anifrolumab in severe active lupus nephritis or severe active CNS lupus—efficacy has not been established in these populations 1.
Dosing and Administration Protocol
Standard Regimen
- Dose: 300 mg IV every 4 weeks 1
- Infusion duration: 30 minutes 1
- Preparation: Dilute 2 mL of anifrolumab into 50-100 mL 0.9% sodium chloride (after removing 2 mL from bag) 1
- Filter requirement: Use sterile, low-protein binding 0.2-15 micron in-line or add-on filter 1
- Line flush: Complete with 25 mL normal saline to ensure full dose delivery 1
Missed Dose Management
If a scheduled infusion is missed, administer as soon as possible but maintain a minimum 14-day interval between infusions 1.
Storage of Prepared Solution
- Immediate use preferred
- Room temperature (59-77°F): up to 4 hours
- Refrigerated (36-46°F): up to 24 hours
- Protect from light; do not freeze 1
Clinical Efficacy Evidence
The TULIP-2 trial demonstrated superiority over placebo with 47.8% achieving BICLA response versus 31.5% with placebo (16.3 percentage point difference, P=0.001) 3. Notably, anifrolumab enables glucocorticoid dose reduction and improves cutaneous manifestations—both critical for long-term morbidity 3.
Recent data suggest anifrolumab may reduce cardiovascular damage accrual, with 0.046 fewer CV-SDI points at 4 years compared to standard care (P=0.008) 4. This addresses a leading cause of mortality in SLE patients.
Onset of action: While full efficacy typically requires weeks, case reports document fever and panniculitis resolution within 24 hours to 2 weeks after a single dose in refractory patients 5.
Safety Monitoring
Key Risks
- Herpes zoster: 7.2% incidence (versus lower with placebo) 3
- Respiratory infections: Increased risk, including bronchitis (12.2%) 3
- Serious infections: Monitor closely; fatal infections reported 1
- Hypersensitivity/anaphylaxis: Contraindicated if prior anaphylaxis to anifrolumab 1
Pre-Treatment Assessment
- Screen for active infections—delay treatment until resolved or adequately treated 1
- Consider pre-medication for patients with prior infusion reactions 1
- Ensure healthcare setting equipped to manage anaphylaxis 1
During Treatment
- Interrupt therapy for clinically significant infections not responding to standard treatment 1
- Counsel patients to report infection symptoms immediately 1
Special Populations
Immunosuppressant-naive patients: Post-hoc analysis of TULIP-1/TULIP-2 demonstrates efficacy regardless of prior immunosuppressant exposure, with DORIS remission rates of 16.2% versus 6.0% placebo in IS-inexperienced patients (P=0.0242) 6. This supports using anifrolumab without requiring prior immunosuppressant failure.
Subcutaneous formulation: A 120 mg weekly subcutaneous formulation showed efficacy in phase 3 trials (BICLA response 59.4% vs 43.9% placebo at interim analysis, P=0.0211) 7, though IV remains the currently approved route.
Treatment Goals
Target LLDAS or DORIS remission, as both correlate with reduced damage accrual, flares, and mortality 2. Anifrolumab facilitates these targets: at week 52, LLDAS attainment was 34.0% versus 26.2% placebo in IS-inexperienced patients 6.
Glucocorticoid reduction: Among patients on ≥10 mg/day prednisone at baseline, 41% achieved sustained reduction to ≤7.5 mg/day with anifrolumab versus 32% with placebo 3. This is critical given the 2024 EULAR recommendation to maintain ≤5 mg/day prednisone due to infection, osteonecrosis, and damage risks 2.